If we say you could live longer now because of AI, would you believe it? Well, Sam Altman is placing another major bet on the future, this time in the field of human longevity. The OpenAI chief has reportedly invested nearly $180 million of his own money into Retro Biosciences, which is a startup working on extending healthy human lifespan and reducing age-related diseases. While that is the core, there is more to know. The company is researching advanced techniques like cellular reprogramming, which aims to make older cells function like younger ones again, along with a few more vital things. What makes the story even more interesting is the growing role of artificial intelligence in the project. Retro Biosciences is collaborating with OpenAI to use AI models for faster protein design and medical research. This investment is a testimony to how multifunctional AI and tech are!
About Retro Biosciences
Retro Biosciences is a biotechnology company focused on increasing healthy human lifespan and fighting diseases associated with aging. Founded in 2021, the startup aims to add around 10 healthy years to human life through advanced medical research and cellular engineering. While this sounds dreamy, it may actually be true. Its work mainly revolves around studying how cells age and finding ways to reverse or slow down that process.
One of the company’s major research areas is “cellular reprogramming,” Which is a cool concept to be honest. It is a technique that attempts to restore aged cells to a younger and healthier state. Retro is also exploring therapies related to blood plasma, stem cells, and targeted medicine. The company has attracted attention because of its close collaboration with artificial intelligence tools, including models developed alongside OpenAI. What we see here is that by combining AI with biotechnology, Retro hopes to speed up scientific discoveries and improvements.
What does this investment mean?
Sam Altman’s massive investment in Retro Biosciences signals that major tech leaders now see longevity research as one of the next big industries after AI. Instead of focusing only on software and automation, investors are now putting money into projects that could change how humans age and treat diseases in the future.
The investment is a win-win as it also reflects confidence in AI-driven scientific research. Drug discovery and biological studies usually take years, or at least used to now, but AI tools can analyze data and predict outcomes much faster. If successful, companies like Retro Biosciences could help develop treatments for age-related illnesses such as Alzheimer’s, cancer, and heart disease more efficiently.
